Physician profile
Melvin Kohan
NPI 1548215460
$1,987.22
in general payments reported to CMS, 2019-2025
16 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $115 · 2021: $48.46 · 2022: $77.08 · 2023: $81.22 · 2024: $417 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $768.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $457.07 | 2024-2025 | Fetroja |
| Gilead Sciences, INC. | $314.50 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $304.67 | 2019-2024 | Dovato |
| Cipla USA INC. | $292.47 | 2019 | |
| Merck Sharp & Dohme LLC | $185.23 | 2019-2024 | Zerbaxa, Dificid, Recarbrio |
| Janssen Biotech, INC. | $96.45 | 2019-2023 | Symtuza |
| Melinta Therapeutics, LLC | $82.84 | 2019-2025 | Rezzayo |
| Abbvie INC. | $79.46 | 2019-2024 | |
| Allergan, INC. | $44.84 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $34.78 | 2019 | |
| Vyera Pharmaceuticals, LLC | $19.17 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.03 | 2020 | |
| Astellas Pharma US INC | $18.01 | 2019 | |
| Insmed, INC. | $16.98 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $11.49 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Kohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.